![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Cepheid Gains FDA Clearance for Strep A Test
Cepheid Gains FDA Clearance for Strep A Test
May 2, 2018
Cepheid, a molecular diagnostics company, received FDA 510(k) clearance for its Xpert Xpress Strep A test to provide molecular detection of Streptococcus pyogenes (Group A Strep).
The test uses an automated real-time polymerase chain reaction to detect Strep A DNA. It can be performed by untrained users to gather results in around 18 minutes.
The low-risk CLIA-waived test does not require culture confirmation for negative results unless symptoms persist or there is an outbreak of acute rheumatic fever.
Upcoming Events
-
21Oct